25 XP   0   0   10

Editas Medicine Inc
Buy, Hold or Sell?

Let's analyse Editas Medicine Inc together

PenkeI guess you are interested in Editas Medicine Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Editas Medicine Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Editas Medicine Inc

I send you an email if I find something interesting about Editas Medicine Inc.

Quick analysis of Editas Medicine Inc (30 sec.)










What can you expect buying and holding a share of Editas Medicine Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
13.5%

What is your share worth?

Current worth
$4.27
Expected worth in 1 year
$4.13
How sure are you?
32.4%

+ What do you gain per year?

Total Gains per Share
$-0.14
Return On Investment
-2.6%

For what price can you sell your share?

Current Price per Share
$5.37
Expected price per share
$0 - $6.88
How sure are you?
50%

1. Valuation of Editas Medicine Inc (5 min.)




Live pricePrice per Share (EOD)

$5.37

Intrinsic Value Per Share

$-4.82 - $-4.93

Total Value Per Share

$-0.55 - $-0.66

2. Growth of Editas Medicine Inc (5 min.)




Is Editas Medicine Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$349m$438.3m-$81.6m-22.9%

How much money is Editas Medicine Inc making?

Current yearPrevious yearGrowGrow %
Making money-$37.4m-$52.9m$15.5m41.5%
Net Profit Margin-683.3%-32,705.5%--

How much money comes from the company's main activities?

3. Financial Health of Editas Medicine Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#156 / 1007

Most Revenue
#232 / 1007

Most Profit
#841 / 1007

Most Efficient
#770 / 1007

What can you expect buying and holding a share of Editas Medicine Inc? (5 min.)

Welcome investor! Editas Medicine Inc's management wants to use your money to grow the business. In return you get a share of Editas Medicine Inc.

What can you expect buying and holding a share of Editas Medicine Inc?

First you should know what it really means to hold a share of Editas Medicine Inc. And how you can make/lose money.

Speculation

The Price per Share of Editas Medicine Inc is $5.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Editas Medicine Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Editas Medicine Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.27. Based on the TTM, the Book Value Change Per Share is $-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Editas Medicine Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.23-4.3%-0.47-8.7%-0.67-12.5%-0.50-9.3%-0.47-8.8%
Usd Book Value Change Per Share-0.14-2.6%-0.04-0.7%-0.59-11.0%0.071.3%0.122.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.14-2.6%-0.04-0.7%-0.59-11.0%0.071.3%0.122.2%
Usd Price Per Share10.13-8.35-12.99-25.04-21.81-
Price to Earnings Ratio-10.98--5.43--4.93--8.02--10.76-
Price-to-Total Gains Ratio-72.92--23.66--22.92--29.61--43.43-
Price to Book Ratio2.37-1.92-2.39-5.50-6.31-
Price-to-Total Gains Ratio-72.92--23.66--22.92--29.61--43.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.37
Number of shares186
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.07
Usd Total Gains Per Share-0.040.07
Gains per Quarter (186 shares)-6.5812.84
Gains per Year (186 shares)-26.3351.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-26-3605141
20-53-62010392
30-79-880154143
40-105-1140205194
50-132-1400257245
60-158-1660308296
70-184-1920359347
80-211-2180411398
90-237-2440462449
100-263-2700514500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.036.00.02.7%1.036.00.02.7%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%12.023.02.032.4%12.023.02.032.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%5.00.032.013.5%5.00.032.013.5%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%12.023.02.032.4%12.023.02.032.4%

Fundamentals of Editas Medicine Inc

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 06:35:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Editas Medicine Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Editas Medicine Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Editas Medicine Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -31.4% means that $-0.31 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Editas Medicine Inc:

  • The MRQ is -31.4%. The company is making a huge loss. -2
  • The TTM is -683.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-31.4%TTM-683.3%+651.9%
TTM-683.3%YOY-32,705.5%+32,022.2%
TTM-683.3%5Y-7,770.6%+7,087.2%
5Y-7,770.6%10Y-5,529.3%-2,241.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-31.4%-207.2%+175.8%
TTM-683.3%-216.8%-466.5%
YOY-32,705.5%-282.4%-32,423.1%
5Y-7,770.6%-434.0%-7,336.6%
10Y-5,529.3%-584.8%-4,944.5%
1.1.2. Return on Assets

Shows how efficient Editas Medicine Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Editas Medicine Inc to the Biotechnology industry mean.
  • -3.8% Return on Assets means that Editas Medicine Inc generated $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Editas Medicine Inc:

  • The MRQ is -3.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.8%TTM-7.5%+3.7%
TTM-7.5%YOY-9.5%+2.0%
TTM-7.5%5Y-7.4%0.0%
5Y-7.4%10Y-20.0%+12.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.8%-13.2%+9.4%
TTM-7.5%-12.7%+5.2%
YOY-9.5%-11.5%+2.0%
5Y-7.4%-13.8%+6.4%
10Y-20.0%-15.5%-4.5%
1.1.3. Return on Equity

Shows how efficient Editas Medicine Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Editas Medicine Inc to the Biotechnology industry mean.
  • -5.4% Return on Equity means Editas Medicine Inc generated $-0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Editas Medicine Inc:

  • The MRQ is -5.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.4%TTM-10.6%+5.2%
TTM-10.6%YOY-12.3%+1.8%
TTM-10.6%5Y-11.0%+0.4%
5Y-11.0%10Y-10.7%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.4%-16.7%+11.3%
TTM-10.6%-15.9%+5.3%
YOY-12.3%-14.7%+2.4%
5Y-11.0%-19.2%+8.2%
10Y-10.7%-20.0%+9.3%

1.2. Operating Efficiency of Editas Medicine Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Editas Medicine Inc is operating .

  • Measures how much profit Editas Medicine Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Editas Medicine Inc to the Biotechnology industry mean.
  • An Operating Margin of -39.9% means the company generated $-0.40  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Editas Medicine Inc:

  • The MRQ is -39.9%. The company is operating very inefficient. -2
  • The TTM is -756.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-39.9%TTM-756.4%+716.5%
TTM-756.4%YOY-34,887.3%+34,130.9%
TTM-756.4%5Y-8,263.9%+7,507.5%
5Y-8,263.9%10Y-5,197.6%-3,066.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.9%-298.0%+258.1%
TTM-756.4%-238.5%-517.9%
YOY-34,887.3%-291.9%-34,595.4%
5Y-8,263.9%-485.6%-7,778.3%
10Y-5,197.6%-610.8%-4,586.8%
1.2.2. Operating Ratio

Measures how efficient Editas Medicine Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.40 means that the operating costs are $1.40 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Editas Medicine Inc:

  • The MRQ is 1.399. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.805. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.399TTM8.805-7.406
TTM8.805YOY359.483-350.678
TTM8.8055Y86.778-77.972
5Y86.77810Y62.057+24.720
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3993.235-1.836
TTM8.8053.310+5.495
YOY359.4833.791+355.692
5Y86.7785.675+81.103
10Y62.0577.558+54.499

1.3. Liquidity of Editas Medicine Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Editas Medicine Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.39 means the company has $5.39 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Editas Medicine Inc:

  • The MRQ is 5.391. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.694. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.391TTM6.694-1.302
TTM6.694YOY10.577-3.883
TTM6.6945Y8.378-1.684
5Y8.37810Y9.754-1.376
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3913.877+1.514
TTM6.6944.178+2.516
YOY10.5775.343+5.234
5Y8.3786.135+2.243
10Y9.7546.468+3.286
1.3.2. Quick Ratio

Measures if Editas Medicine Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Editas Medicine Inc to the Biotechnology industry mean.
  • A Quick Ratio of 8.43 means the company can pay off $8.43 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Editas Medicine Inc:

  • The MRQ is 8.427. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.928. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.427TTM10.928-2.501
TTM10.928YOY16.710-5.781
TTM10.9285Y13.095-2.167
5Y13.09510Y13.467-0.372
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4273.514+4.913
TTM10.9283.998+6.930
YOY16.7105.380+11.330
5Y13.0956.135+6.960
10Y13.4676.434+7.033

1.4. Solvency of Editas Medicine Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Editas Medicine Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Editas Medicine Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30 means that Editas Medicine Inc assets are financed with 30.1% credit (debt) and the remaining percentage (100% - 30.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Editas Medicine Inc:

  • The MRQ is 0.301. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.291. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.301TTM0.291+0.010
TTM0.291YOY0.223+0.068
TTM0.2915Y0.301-0.010
5Y0.30110Y0.520-0.219
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3010.339-0.038
TTM0.2910.336-0.045
YOY0.2230.271-0.048
5Y0.3010.368-0.067
10Y0.5200.388+0.132
1.4.2. Debt to Equity Ratio

Measures if Editas Medicine Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Editas Medicine Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 43.0% means that company has $0.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Editas Medicine Inc:

  • The MRQ is 0.430. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.412. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.430TTM0.412+0.018
TTM0.412YOY0.292+0.119
TTM0.4125Y0.468-0.056
5Y0.46810Y0.480-0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4300.388+0.042
TTM0.4120.403+0.009
YOY0.2920.340-0.048
5Y0.4680.430+0.038
10Y0.4800.463+0.017

2. Market Valuation of Editas Medicine Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Editas Medicine Inc generates.

  • Above 15 is considered overpriced but always compare Editas Medicine Inc to the Biotechnology industry mean.
  • A PE ratio of -10.98 means the investor is paying $-10.98 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Editas Medicine Inc:

  • The EOD is -5.819. Based on the earnings, the company is expensive. -2
  • The MRQ is -10.978. Based on the earnings, the company is expensive. -2
  • The TTM is -5.431. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.819MRQ-10.978+5.158
MRQ-10.978TTM-5.431-5.547
TTM-5.431YOY-4.927-0.504
TTM-5.4315Y-8.017+2.586
5Y-8.01710Y-10.756+2.740
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.819-2.281-3.538
MRQ-10.978-2.599-8.379
TTM-5.431-2.674-2.757
YOY-4.927-4.133-0.794
5Y-8.017-6.258-1.759
10Y-10.756-6.270-4.486
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Editas Medicine Inc:

  • The EOD is -4.665. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.799. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.354. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.665MRQ-8.799+4.135
MRQ-8.799TTM-5.354-3.445
TTM-5.354YOY-5.806+0.452
TTM-5.3545Y-11.506+6.152
5Y-11.50610Y-158.395+146.889
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.665-2.903-1.762
MRQ-8.799-3.323-5.476
TTM-5.354-3.552-1.802
YOY-5.806-5.592-0.214
5Y-11.506-8.378-3.128
10Y-158.395-8.875-149.520
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Editas Medicine Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.37 means the investor is paying $2.37 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Editas Medicine Inc:

  • The EOD is 1.259. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.374. Based on the equity, the company is underpriced. +1
  • The TTM is 1.924. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.259MRQ2.374-1.116
MRQ2.374TTM1.924+0.450
TTM1.924YOY2.385-0.461
TTM1.9245Y5.499-3.575
5Y5.49910Y6.311-0.812
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2591.911-0.652
MRQ2.3742.116+0.258
TTM1.9242.097-0.173
YOY2.3852.885-0.500
5Y5.4993.556+1.943
10Y6.3113.959+2.352
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Editas Medicine Inc.

3.1. Institutions holding Editas Medicine Inc

Institutions are holding 75.605% of the shares of Editas Medicine Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Vanguard Group Inc10.45160.001685362083707344.5403
2023-09-30BlackRock Inc9.9910.001881600335643377.4297
2023-09-30Deep Track Capital, LP8.69552.138171019353648191105.63
2023-09-30State Street Corporation7.06590.00255770942-870737-13.1102
2023-09-30Woodline Partners LP3.99110.2981325971051040518.5649
2023-12-31Dimensional Fund Advisors, Inc.2.92920.0071239239669036640.5613
2023-09-30Marshall Wace Asset Management Ltd2.68730.03472194806-643511-22.6723
2023-09-30Geode Capital Management, LLC2.21370.0017180797931515621.1114
2023-09-30Pictet Asset Manangement SA2.2040.0173180010118001010
2023-09-30Morgan Stanley - Brokerage Accounts1.63420.00111334697-370261-21.7167
2023-09-30Two Sigma Investments LLC1.54830.0265126458827816828.1998
2023-09-30Millennium Management LLC1.42610.00461164773-205049-14.969
2023-09-30Credit Suisse First Boston (CSFB)1.39870.00911142341686616.3949
2023-09-30Two Sigma Advisers, LLC1.31620.0215107500028460036.0071
2023-09-30JPMorgan Chase & Co1.29820.00091060291-64214-5.7104
2023-09-30Nuveen Asset Management, LLC1.16210.002694911526345838.4242
2023-09-30Northern Trust Corp1.08820.001388874612463716.3114
2023-09-30Charles Schwab Investment Management Inc0.84360.001568896417069432.9353
2023-09-30D. E. Shaw & Co LP0.81880.0055668745-117324-14.9254
2023-09-30Man Group PLC0.78140.0154638182-101992-13.7795
Total 63.54512.592951899552+6716420+12.9%

3.2. Funds holding Editas Medicine Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF8.20660.65986714176846801.2773
2024-02-29Vanguard Total Stock Mkt Idx Inv3.13430.00172564306-33700-1.2971
2024-02-29Vanguard Small Cap Index2.5730.01512105099194470.9324
2024-03-28iShares Russell 2000 ETF2.48250.02320310129780.0482
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.55250.012512701955360.0422
2024-02-29Vanguard Small Cap Growth Index Inv1.44420.03411181555196031.6871
2023-10-13Pictet Biopharmaceutical Mother1.12570.432492100039718575.8254
2024-02-29JPM Thematics Genetic Thrps C2 Acc USD1.1031.2339902408-13654-1.4905
2024-01-31Fidelity Small Cap Index1.01560.0236830924108231.3197
2024-03-31Direxion Daily S&P Biotech Bull 3X ETF0.9850.4788805887-5654-0.6967
2024-03-28iShares Russell 2000 Value ETF0.95190.0461778748-494-0.0634
2024-02-29CS (Lux) Digital Health Equity SB USD0.91670.484475000000
2024-01-31TIAA-CREF Quant Small-Cap Equity Instl0.84040.161468756028736071.8041
2024-03-28iShares Biotechnology ETF0.74690.059461102900
2024-02-29Fidelity Extended Market Index0.64340.01385263887075015.5277
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.60690.01249654098002.0134
2023-12-31Vanguard Strategic Equity Inv0.5950.0633486795-195658-28.6698
2024-03-31Selectra J. Lamarck Biotech A0.50042.8549409400124273.1304
2024-02-29DFA US Targeted Value I0.47880.030539171300
2024-03-29Schwab US Small-Cap ETF™0.4670.016638207800
Total 30.36986.657324846813+664429+2.7%

3.3. Insider Transactions

Insiders are holding 0.912% of the shares of Editas Medicine Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-05Gilmore Neil O'neillSELL778249.42
2024-03-04Baisong MeiSELL203279.42
2023-12-05Bruce EatonSELL10310.9
2023-11-07Bruce EatonSELL1398.4
2023-09-06Bruce EatonSELL1038.82
2023-08-11Bruce EatonSELL7028.59
2023-08-08Bruce EatonSELL1418.39
2023-07-19Baisong MeiSELL43178.8
2023-06-05Bruce EatonSELL1059.5
2023-06-05Gilmore Neil O'neillSELL64869.5
2023-05-11Bruce EatonSELL6689.87
2023-05-11Michelle RobertsonSELL9499.87
2023-05-09Bruce EatonSELL1359.51

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Editas Medicine Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.139-0.035-75%-0.590+324%0.069-301%0.115-220%
Book Value Per Share--4.2674.360-2%5.359-20%4.859-12%3.422+25%
Current Ratio--5.3916.694-19%10.577-49%8.378-36%9.754-45%
Debt To Asset Ratio--0.3010.291+3%0.223+35%0.3010%0.520-42%
Debt To Equity Ratio--0.4300.412+4%0.292+47%0.468-8%0.480-10%
Dividend Per Share----0%-0%-0%0.001-100%
Eps---0.231-0.468+103%-0.674+192%-0.499+116%-0.472+105%
Free Cash Flow Per Share---0.288-0.418+45%-0.555+93%-0.442+54%-0.281-2%
Free Cash Flow To Equity Per Share---0.282-0.046-84%-0.551+96%0.023-1339%0.133-312%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.928--------
Intrinsic Value_10Y_min---4.819--------
Intrinsic Value_1Y_max---1.782--------
Intrinsic Value_1Y_min---1.751--------
Intrinsic Value_3Y_max---4.372--------
Intrinsic Value_3Y_min---4.194--------
Intrinsic Value_5Y_max---5.779--------
Intrinsic Value_5Y_min---5.448--------
Market Cap439340106.000-89%828773794.000683349764.500+21%1062761262.000-22%2048453924.400-60%1783983076.757-54%
Net Profit Margin---0.314-6.833+2074%-327.055+103955%-77.706+24623%-55.293+17492%
Operating Margin---0.399-7.564+1796%-348.873+87328%-82.639+20609%-51.976+12925%
Operating Ratio--1.3998.805-84%359.483-100%86.778-98%62.057-98%
Pb Ratio1.259-89%2.3741.924+23%2.3850%5.499-57%6.311-62%
Pe Ratio-5.819+47%-10.978-5.431-51%-4.927-55%-8.017-27%-10.756-2%
Price Per Share5.370-89%10.1308.353+21%12.990-22%25.038-60%21.805-54%
Price To Free Cash Flow Ratio-4.665+47%-8.799-5.354-39%-5.806-34%-11.506+31%-158.395+1700%
Price To Total Gains Ratio-38.657+47%-72.923-23.665-68%-22.923-69%-29.608-59%-43.426-40%
Quick Ratio--8.42710.928-23%16.710-50%13.095-36%13.467-37%
Return On Assets---0.038-0.075+98%-0.095+151%-0.074+97%-0.200+429%
Return On Equity---0.054-0.106+96%-0.123+128%-0.110+104%-0.107+98%
Total Gains Per Share---0.139-0.035-75%-0.590+324%0.069-301%0.116-220%
Usd Book Value--349097000.000356737250.000-2%438399750.000-20%397553450.000-12%279998972.973+25%
Usd Book Value Change Per Share---0.139-0.035-75%-0.590+324%0.069-301%0.115-220%
Usd Book Value Per Share--4.2674.360-2%5.359-20%4.859-12%3.422+25%
Usd Dividend Per Share----0%-0%-0%0.001-100%
Usd Eps---0.231-0.468+103%-0.674+192%-0.499+116%-0.472+105%
Usd Free Cash Flow---23547000.000-34224250.000+45%-45366750.000+93%-36199250.000+54%-22970432.432-2%
Usd Free Cash Flow Per Share---0.288-0.418+45%-0.555+93%-0.442+54%-0.281-2%
Usd Free Cash Flow To Equity Per Share---0.282-0.046-84%-0.551+96%0.023-1339%0.133-312%
Usd Market Cap439340106.000-89%828773794.000683349764.500+21%1062761262.000-22%2048453924.400-60%1783983076.757-54%
Usd Price Per Share5.370-89%10.1308.353+21%12.990-22%25.038-60%21.805-54%
Usd Profit---18874000.000-37437500.000+98%-52979500.000+181%-40194600.000+113%-32693621.622+73%
Usd Revenue--60049000.00019530750.000+207%4927750.000+1119%11732050.000+412%7783459.459+671%
Usd Total Gains Per Share---0.139-0.035-75%-0.590+324%0.069-301%0.116-220%
 EOD+3 -5MRQTTM+17 -16YOY+22 -115Y+17 -1610Y+17 -18

4.2. Fundamental Score

Let's check the fundamental score of Editas Medicine Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.819
Price to Book Ratio (EOD)Between0-11.259
Net Profit Margin (MRQ)Greater than0-0.314
Operating Margin (MRQ)Greater than0-0.399
Quick Ratio (MRQ)Greater than18.427
Current Ratio (MRQ)Greater than15.391
Debt to Asset Ratio (MRQ)Less than10.301
Debt to Equity Ratio (MRQ)Less than10.430
Return on Equity (MRQ)Greater than0.15-0.054
Return on Assets (MRQ)Greater than0.05-0.038
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Editas Medicine Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5027.635
Ma 20Greater thanMa 506.066
Ma 50Greater thanMa 1007.476
Ma 100Greater thanMa 2008.253
OpenGreater thanClose5.380
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -3,6011,322-2,279-6-2,285833-1,4521,650198



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets499,153
Total Liabilities150,056
Total Stockholder Equity349,097
 As reported
Total Liabilities 150,056
Total Stockholder Equity+ 349,097
Total Assets = 499,153

Assets

Total Assets499,153
Total Current Assets340,829
Long-term Assets158,324
Total Current Assets
Cash And Cash Equivalents 123,652
Short-term Investments 199,459
Net Receivables 10,187
Other Current Assets 7,531
Total Current Assets  (as reported)340,829
Total Current Assets  (calculated)340,829
+/-0
Long-term Assets
Property Plant Equipment 45,712
Long Term Investments 104,024
Long-term Assets Other 4,711
Long-term Assets  (as reported)158,324
Long-term Assets  (calculated)154,447
+/- 3,877

Liabilities & Shareholders' Equity

Total Current Liabilities63,217
Long-term Liabilities86,839
Total Stockholder Equity349,097
Total Current Liabilities
Short-term Debt 12,164
Accounts payable 8,269
Other Current Liabilities 34,563
Total Current Liabilities  (as reported)63,217
Total Current Liabilities  (calculated)54,996
+/- 8,221
Long-term Liabilities
Capital Lease Obligations 36,536
Long-term Liabilities Other 1,800
Long-term Liabilities  (as reported)86,839
Long-term Liabilities  (calculated)38,336
+/- 48,503
Total Stockholder Equity
Common Stock8
Retained Earnings -1,231,350
Accumulated Other Comprehensive Income 198
Other Stockholders Equity 1,580,241
Total Stockholder Equity (as reported)349,097
Total Stockholder Equity (calculated)349,097
+/-0
Other
Capital Stock8
Cash and Short Term Investments 323,111
Common Stock Shares Outstanding 81,710
Current Deferred Revenue8,221
Liabilities and Stockholders Equity 499,153
Net Debt -87,116
Net Invested Capital 349,097
Net Working Capital 277,612
Property Plant and Equipment Gross 71,972
Short Long Term Debt Total 36,536



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312013-12-31
> Total Assets 
2,481
12,188
0
0
159,745
149,363
248,808
249,602
242,153
229,182
395,041
368,849
339,127
373,260
403,982
393,530
387,630
420,386
378,916
355,625
372,359
508,885
466,737
655,481
597,157
572,602
780,294
755,880
717,019
677,483
623,108
580,833
531,029
514,321
464,105
541,953
504,650
499,153
499,153504,650541,953464,105514,321531,029580,833623,108677,483717,019755,880780,294572,602597,157655,481466,737508,885372,359355,625378,916420,386387,630393,530403,982373,260339,127368,849395,041229,182242,153249,602248,808149,363159,7450012,1882,481
   > Total Current Assets 
0
10,716
0
0
156,941
144,985
232,186
221,218
203,449
187,183
353,786
327,872
298,416
332,199
362,812
348,237
342,553
374,776
347,067
324,240
339,211
463,844
425,106
610,126
506,827
419,087
632,316
616,292
567,608
507,310
497,031
461,377
426,629
356,754
324,458
440,978
446,414
340,829
340,829446,414440,978324,458356,754426,629461,377497,031507,310567,608616,292632,316419,087506,827610,126425,106463,844339,211324,240347,067374,776342,553348,237362,812332,199298,416327,872353,786187,183203,449221,218232,186144,985156,9410010,7160
       Cash And Cash Equivalents 
2,012
10,623
0
0
155,301
143,180
229,204
217,650
199,874
185,323
351,552
144,096
86,542
146,630
217,671
131,924
111,701
134,776
157,932
210,605
104,772
238,183
232,850
485,819
279,576
139,682
354,918
337,834
259,884
203,519
210,881
169,401
210,704
141,522
129,021
220,817
82,537
123,652
123,65282,537220,817129,021141,522210,704169,401210,881203,519259,884337,834354,918139,682279,576485,819232,850238,183104,772210,605157,932134,776111,701131,924217,671146,63086,542144,096351,552185,323199,874217,650229,204143,180155,3010010,6232,012
       Short-term Investments 
0
0
0
0
370
320
320
320
320
0
0
180,699
209,149
182,509
141,150
212,156
225,791
234,179
184,133
107,325
227,844
218,957
182,143
112,901
215,729
262,428
270,415
272,719
297,957
296,326
277,481
283,157
208,913
202,752
189,418
211,151
267,080
199,459
199,459267,080211,151189,418202,752208,913283,157277,481296,326297,957272,719270,415262,428215,729112,901182,143218,957227,844107,325184,133234,179225,791212,156141,150182,509209,149180,699003203203203203700000
       Net Receivables 
0
1,019
0
0
1,040
1,019
1,108
1,195
1,122
88
945
820
695
679
931
362
43
30
30
12
311
418
1,832
1,865
1,055
6,048
672
331
251
267
1,371
713
120
5,145
242
2,286
2,422
10,187
10,1872,4222,2862425,1451207131,3712672513316726,0481,0551,8651,83241831112303043362931679695820945881,1221,1951,1081,0191,040001,0190
       Inventory 
0
0
0
0
0
780
0
0
0
1,662
0
0
0
1,864
0
0
0
2,918
0
0
0
0
0
0
-45,986
-109,664
-97,890
-87,584
0
-120,070
0
0
0
-93,097
-83,339
-48,065
-8,986
0
0-8,986-48,065-83,339-93,097000-120,0700-87,584-97,890-109,664-45,9860000002,9180001,8640001,66200078000000
   > Long-term Assets 
0
1,472
0
0
2,804
4,378
16,622
28,384
38,704
41,999
41,255
40,977
40,711
41,061
41,170
45,293
45,077
45,610
31,849
31,385
33,148
45,041
41,631
45,355
90,330
153,515
147,978
139,588
149,411
170,173
126,077
119,456
104,400
157,567
139,647
100,975
58,236
158,324
158,32458,236100,975139,647157,567104,400119,456126,077170,173149,411139,588147,978153,51590,33045,35541,63145,04133,14831,38531,84945,61045,07745,29341,17041,06140,71140,97741,25541,99938,70428,38416,6224,3782,804001,4720
       Property Plant Equipment 
52
1,112
0
0
2,143
2,130
15,003
26,741
37,072
40,378
39,636
39,358
39,092
39,442
39,551
39,915
39,699
40,232
26,471
26,007
27,756
39,648
39,240
41,464
40,467
39,148
43,400
45,224
43,432
43,291
40,715
36,864
38,026
59,217
49,555
47,657
43,495
45,712
45,71243,49547,65749,55559,21738,02636,86440,71543,29143,43245,22443,40039,14840,46741,46439,24039,64827,75626,00726,47140,23239,69939,91539,55139,44239,09239,35839,63640,37837,07226,74115,0032,1302,143001,11252
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,667
3,667
3,667
3,667
3,667
0
0
45,986
109,664
97,890
87,584
99,198
120,071
78,046
75,062
58,844
93,097
83,339
48,065
96,797
104,024
104,02496,79748,06583,33993,09758,84475,06278,046120,07199,19887,58497,890109,66445,986003,6673,6673,6673,6673,66700000000000000000
       Long-term Assets Other 
0
360
0
0
661
2,248
1,619
1,643
1,632
1,621
1,619
1,619
1,619
1,619
1,619
5,378
5,378
5,378
5,378
5,378
5,392
5,393
2,391
3,891
3,877
4,703
6,688
6,780
6,781
6,811
7,316
7,530
7,530
5,253
6,753
5,253
-82,056
4,711
4,711-82,0565,2536,7535,2537,5307,5307,3166,8116,7816,7806,6884,7033,8773,8912,3915,3935,3925,3785,3785,3785,3785,3781,6191,6191,6191,6191,6191,6211,6321,6431,6192,248661003600
> Total Liabilities 
2,133
27,480
0
0
32,129
232,477
47,445
62,272
71,977
94,575
188,580
183,845
161,339
165,180
156,467
162,198
163,181
184,224
161,754
162,563
162,369
246,448
232,170
228,709
156,005
179,016
142,298
142,519
130,225
123,841
110,348
115,419
116,284
153,641
146,632
142,036
144,188
150,056
150,056144,188142,036146,632153,641116,284115,419110,348123,841130,225142,519142,298179,016156,005228,709232,170246,448162,369162,563161,754184,224163,181162,198156,467165,180161,339183,845188,58094,57571,97762,27247,445232,47732,1290027,4802,133
   > Total Current Liabilities 
2,128
6,161
0
0
5,476
6,925
10,222
13,721
13,757
33,083
50,287
48,686
29,496
36,707
30,994
24,020
26,086
35,900
41,029
72,867
66,787
59,963
68,869
68,150
54,816
58,208
64,010
66,016
50,907
46,884
36,503
36,421
42,289
60,110
57,155
54,513
58,603
63,217
63,21758,60354,51357,15560,11042,28936,42136,50346,88450,90766,01664,01058,20854,81668,15068,86959,96366,78772,86741,02935,90026,08624,02030,99436,70729,49648,68650,28733,08313,75713,72110,2226,9255,476006,1612,128
       Short-term Debt 
0
67
0
0
448
10,000
-25,479
-25,642
-16,308
10,000
15,000
15,000
8,450
7,500
7,767
11,029
11,341
12,813
3,519
3,648
4,448
5,804
5,649
6,650
6,342
6,811
7,264
8,974
10,263
10,309
10,206
10,147
11,973
11,082
8,327
10,330
9,693
12,164
12,1649,69310,3308,32711,08211,97310,14710,20610,30910,2638,9747,2646,8116,3426,6505,6495,8044,4483,6483,51912,81311,34111,0297,7677,5008,45015,00015,00010,000-16,308-25,642-25,47910,00044800670
       Short Long Term Debt 
0
67
0
0
0
10,000
0
10,000
10,000
45,096
15,000
48,878
33,667
40,931
33,190
32,944
0
0
3,519
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000003,5190032,94433,19040,93133,66748,87815,00045,09610,00010,000010,000000670
       Accounts payable 
404
2,595
0
0
1,515
1,381
2,909
5,844
3,718
4,640
15,233
8,156
6,976
4,020
8,996
4,661
5,040
5,327
6,557
3,981
6,624
5,843
10,394
6,339
5,158
6,408
8,910
4,415
3,402
5,050
4,693
6,169
6,836
9,511
9,047
8,066
10,411
8,269
8,26910,4118,0669,0479,5116,8366,1694,6935,0503,4024,4158,9106,4085,1586,33910,3945,8436,6243,9816,5575,3275,0404,6618,9964,0206,9768,15615,2334,6403,7185,8442,9091,3811,515002,595404
       Other Current Liabilities 
1,724
1,814
0
0
3,513
5,456
7,313
7,877
547
-7,557
-83,979
12,291
831
11,949
908
944
980
2,048
7,553
9,202
9,696
24,802
12,184
14,221
23,442
24,046
15,132
18,627
14,575
20,192
15,787
-48,783
19,259
31,296
31,560
27,896
30,278
34,563
34,56330,27827,89631,56031,29619,259-48,78315,78720,19214,57518,62715,13224,04623,44214,22112,18424,8029,6969,2027,5532,04898094490811,94983112,291-83,979-7,5575477,8777,3135,4563,513001,8141,724
   > Long-term Liabilities 
0
21,319
0
0
26,653
225,552
37,223
48,551
58,220
61,492
138,293
135,159
131,843
128,473
125,473
138,178
137,095
148,324
120,725
89,696
95,582
186,485
163,301
160,559
101,189
120,808
78,288
76,503
79,318
76,957
73,845
78,998
73,995
93,531
89,477
87,523
60,667
86,839
86,83960,66787,52389,47793,53173,99578,99873,84576,95779,31876,50378,288120,808101,189160,559163,301186,48595,58289,696120,725148,324137,095138,178125,473128,473131,843135,159138,29361,49258,22048,55137,223225,55226,6530021,3190
       Long term Debt Total 
0
0
0
0
0
0
11,649
22,676
32,048
35,096
33,929
33,878
33,667
33,431
33,190
32,944
32,694
32,417
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000032,41732,69432,94433,19033,43133,66733,87833,92935,09632,04822,67611,649000000
       Capital Lease Obligations Min Short Term Debt
0
-67
0
0
-448
-10,000
37,128
48,318
48,356
25,096
18,929
18,878
25,217
25,931
25,423
21,915
21,353
19,604
14,859
13,784
13,202
23,277
21,530
22,153
20,368
19,324
21,621
21,282
18,430
16,069
12,957
10,110
9,328
32,864
28,810
26,856
24,918
24,372
24,37224,91826,85628,81032,8649,32810,11012,95716,06918,43021,28221,62119,32420,36822,15321,53023,27713,20213,78414,85919,60421,35321,91525,42325,93125,21718,87818,92925,09648,35648,31837,128-10,000-44800-670
       Long-term Liabilities Other 
0
0
0
0
0
0
95
233
372
396
331
328
325
317
92,283
105,234
104,401
115,907
1
1
1
1
1
160,559
101,189
120,808
78,288
76,503
79,318
76,957
73,845
78,998
73,995
93,531
89,477
87,523
0
1,800
1,800087,52389,47793,53173,99578,99873,84576,95779,31876,50378,288120,808101,189160,55911111115,907104,401105,23492,28331732532833139637223395000000
       Deferred Long Term Liability 
0
91
0
0
0
25,321
25,479
25,642
25,800
26,000
104,033
100,953
97,851
94,725
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000094,72597,851100,953104,03326,00025,80025,64225,47925,321000910
> Total Stockholder Equity
348
-15,292
0
0
127,616
-83,114
201,363
187,330
170,176
134,607
206,461
185,004
177,788
208,080
247,515
231,332
224,449
236,162
217,162
193,062
209,990
262,437
234,567
426,772
441,152
393,586
637,996
613,361
586,794
553,642
512,760
465,414
414,745
360,680
317,473
399,917
360,462
349,097
349,097360,462399,917317,473360,680414,745465,414512,760553,642586,794613,361637,996393,586441,152426,772234,567262,437209,990193,062217,162236,162224,449231,332247,515208,080177,788185,004206,461134,607170,176187,330201,363-83,114127,61600-15,292348
   Common Stock
0
4
0
0
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
6
6
6
7
7
7
7
7
7
7
7
7
8
8
8
88877777777766655555555444444444430040
   Retained Earnings Total Equity00-1,167,457-1,127,167-1,078,131-1,017,393-961,667-908,214-857,699-816,263-777,181-721,925-665,197-602,698-610,517-586,945-549,221-511,451-478,510-444,724-416,278-391,223-375,985-337,262-305,850-269,661-243,062-216,623-185,526-146,150-125,130-106,089000000
   Accumulated Other Comprehensive Income 
0
-158
0
0
-481
-629
-248,808
-249,602
-242,153
-1,556
-2,163
-67
-23
-76
-52
1
-82
-29
29
45
39
107
694
183
-48
-46
-73
-71
-64
-493
-2,509
-3,387
-4,291
-3,601
-2,279
-2,285
-1,452
198
198-1,452-2,285-2,279-3,601-4,291-3,387-2,509-493-64-71-73-46-48183694107394529-29-821-52-76-23-67-2,163-1,556-242,153-249,602-248,808-629-48100-1580
   Capital Surplus 
0
0
0
0
0
0
307,448
312,456
316,322
320,129
423,080
428,129
447,468
514,002
584,825
607,311
615,749
652,464
661,852
671,522
721,397
811,546
820,813
1,037,100
1,043,892
1,058,823
1,359,987
1,390,606
1,403,114
1,411,827
1,423,476
1,430,461
1,436,422
1,442,405
1,446,912
1,569,651
0
0
001,569,6511,446,9121,442,4051,436,4221,430,4611,423,4761,411,8271,403,1141,390,6061,359,9871,058,8231,043,8921,037,100820,813811,546721,397671,522661,852652,464615,749607,311584,825514,002447,468428,129423,080320,129316,322312,456307,448000000
   Treasury Stock00000000000000000000000000000000000000
   Other Stockholders Equity 
0
156
0
0
203,323
5,234
307,448
312,456
316,322
320,129
423,080
428,129
447,468
514,002
584,825
607,311
615,749
652,464
661,852
671,522
721,397
811,546
820,813
1,037,100
1,043,892
1,058,823
1,359,987
1,390,606
1,403,114
1,411,827
1,423,476
1,430,461
1,436,422
1,442,405
1,446,912
1,569,651
1,574,382
1,580,241
1,580,2411,574,3821,569,6511,446,9121,442,4051,436,4221,430,4611,423,4761,411,8271,403,1141,390,6061,359,9871,058,8231,043,8921,037,100820,813811,546721,397671,522661,852652,464615,749607,311584,825514,002447,468428,129423,080320,129316,322312,456307,4485,234203,323001560



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue78,123
Cost of Revenue-6,064
Gross Profit72,05972,059
 
Operating Income (+$)
Gross Profit72,059
Operating Expense-241,240
Operating Income-169,181-169,181
 
Operating Expense (+$)
Research Development171,587
Selling General Administrative69,653
Selling And Marketing Expenses0
Operating Expense241,240241,240
 
Net Interest Income (+$)
Interest Income13,883
Interest Expense-0
Other Finance Cost-0
Net Interest Income13,883
 
Pretax Income (+$)
Operating Income-169,181
Net Interest Income13,883
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-153,219-185,143
EBIT - interestExpense = -169,181
-153,219
-153,219
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-169,181-153,219
Earnings Before Interest and Taxes (EBITDA)-163,117
 
After tax Income (+$)
Income Before Tax-153,219
Tax Provision-0
Net Income From Continuing Ops-195,083-153,219
Net Income-153,219
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses247,304
Total Other Income/Expenses Net15,962-13,883
 

Technical Analysis of Editas Medicine Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Editas Medicine Inc. The general trend of Editas Medicine Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Editas Medicine Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Editas Medicine Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.0799 < 6.14 < 6.88.

The bearish price targets are: .

Tweet this
Editas Medicine Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Editas Medicine Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Editas Medicine Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Editas Medicine Inc. The current macd is -0.62265029.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Editas Medicine Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Editas Medicine Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Editas Medicine Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Editas Medicine Inc Daily Moving Average Convergence/Divergence (MACD) ChartEditas Medicine Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Editas Medicine Inc. The current adx is 34.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Editas Medicine Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Editas Medicine Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Editas Medicine Inc. The current sar is 5.856496.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Editas Medicine Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Editas Medicine Inc. The current rsi is 27.63. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
Editas Medicine Inc Daily Relative Strength Index (RSI) ChartEditas Medicine Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Editas Medicine Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Editas Medicine Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Editas Medicine Inc Daily Stochastic Oscillator ChartEditas Medicine Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Editas Medicine Inc. The current cci is -79.77539549.

Editas Medicine Inc Daily Commodity Channel Index (CCI) ChartEditas Medicine Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Editas Medicine Inc. The current cmo is -48.78741614.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Editas Medicine Inc Daily Chande Momentum Oscillator (CMO) ChartEditas Medicine Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Editas Medicine Inc. The current willr is -84.61538462.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Editas Medicine Inc Daily Williams %R ChartEditas Medicine Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Editas Medicine Inc.

Editas Medicine Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Editas Medicine Inc. The current atr is 0.35734122.

Editas Medicine Inc Daily Average True Range (ATR) ChartEditas Medicine Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Editas Medicine Inc. The current obv is -43,654,142.

Editas Medicine Inc Daily On-Balance Volume (OBV) ChartEditas Medicine Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Editas Medicine Inc. The current mfi is 23.62.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Editas Medicine Inc Daily Money Flow Index (MFI) ChartEditas Medicine Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Editas Medicine Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Editas Medicine Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Editas Medicine Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5027.635
Ma 20Greater thanMa 506.066
Ma 50Greater thanMa 1007.476
Ma 100Greater thanMa 2008.253
OpenGreater thanClose5.380
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Editas Medicine Inc with someone you think should read this too:
  • Are you bullish or bearish on Editas Medicine Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Editas Medicine Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Editas Medicine Inc

I send you an email if I find something interesting about Editas Medicine Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Editas Medicine Inc.

Receive notifications about Editas Medicine Inc in your mailbox!